[Federal Register Volume 81, Number 215 (Monday, November 7, 2016)]
[Notices]
[Pages 78163-78166]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-26793]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2016-N-3585]
Agency Information Collection Activities; Proposed Collection;
Comment Request; Character-Space-Limited Online Prescription Drug
Communications
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing an
opportunity for public comment on the proposed collection of certain
information by the Agency. Under the Paperwork Reduction Act of 1995
(the PRA), Federal Agencies are required to publish notice in the
Federal Register concerning each proposed collection of information and
to allow 60 days for public comment in response to the notice. This
notice solicits comments on research entitled, ``Character-Space-
Limited Online Prescription Drug Communications.'' The objective of
this research is to test whether a link to prescription drug risk
information can effectively convey the risks associated with a drug
when benefit claims about that drug are made within character-space-
limited communications used in prescription drug promotion.
DATES: Submit either electronic or written comments on the collection
of information by January 6, 2017.
ADDRESSES: You may submit comments as follows:
Electronic Submissions
Submit electronic comments in the following way:
Federal eRulemaking Portal: http://www.regulations.gov.
Follow the instructions for submitting comments. Comments submitted
electronically, including attachments, to http://www.regulations.gov
will be posted to the docket unchanged. Because your comment will be
made public, you are solely responsible for ensuring that your comment
does not include any confidential information that you or a third party
may not wish to be posted, such as medical information, your or anyone
else's Social Security number, or confidential business information,
such as a manufacturing process. Please note that if you include your
name, contact information, or other information that identifies you in
the body of your comments, that information will be posted on http://www.regulations.gov.
If you want to submit a comment with confidential
information that you do not wish to be made available to the public,
submit the comment as a written/paper submission and in the manner
detailed (see ``Written/Paper Submissions'' and ``Instructions'').
Written/Paper Submissions
Submit written/paper submissions as follows:
Mail/Hand delivery/Courier (for written/paper
submissions): Division of Dockets Management (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
For written/paper comments submitted to the Division of
Dockets Management, FDA will post your comment, as well as any
attachments, except for information submitted, marked and identified,
as confidential, if submitted as detailed in ``Instructions.''
Instructions: All submissions received must include the Docket No.
FDA-2016-N-3585 for ``Character-Space-Limited Online Prescription Drug
Communications.'' Received comments will be placed in the docket and,
except for those submitted as ``Confidential Submissions,'' publicly
viewable at http://www.regulations.gov or at the Division of Dockets
Management between 9 a.m. and 4 p.m., Monday through Friday.
Confidential Submissions--To submit a comment with
confidential information that you do not wish to be made publicly
available, submit your comments only as a written/paper submission. You
should submit two copies total. One copy will include the information
you claim to be confidential with a heading or cover note that states
``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will
review this copy, including the claimed confidential information, in
its consideration of comments. The second copy, which will have the
claimed confidential information redacted/blacked out, will be
available for public viewing and posted on http://www.regulations.gov.
Submit both copies to the Division of Dockets Management. If you do not
wish your name and contact information to be made publicly available,
you can provide this information on the cover sheet and not in the body
of your comments and you must identify this information as
``confidential.'' Any information marked as ``confidential'' will not
be disclosed except in accordance with 21 CFR 10.20 and other
applicable disclosure law. For more information about FDA's posting of
comments to public dockets, see 80 FR 56469, September 18, 2015, or
access the information at: http://www.fda.gov/regulatoryinformation/dockets/default.htm.
Docket: For access to the docket to read background documents or
the electronic and written/paper comments received, go to http://www.regulations.gov and insert the docket number, found in brackets in
the heading of this document, into the ``Search'' box and follow the
prompts and/or go to the Division of Dockets Management, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
FOR FURTHER INFORMATION CONTACT: FDA PRA Staff, Office of Operations,
Food and Drug Administration, Three White Flint North, 10A63, 11601
Landsdown St., North Bethesda, MD 20852, [email protected].
SUPPLEMENTARY INFORMATION:
I. Background
Under the PRA (44 U.S.C. 3501-3520), Federal Agencies must obtain
approval from the Office of Management and Budget (OMB) for each
collection of information they conduct or sponsor. ``Collection of
information'' is defined in 44 U.S.C. 3502(3) and 5 CFR 1320.3(c) and
includes Agency requests or requirements that members of the
[[Page 78164]]
public submit reports, keep records, or provide information to a third
party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A))
requires Federal Agencies to provide a 60-day notice in the Federal
Register concerning each proposed collection of information before
submitting the collection to OMB for approval. To comply with this
requirement, FDA is publishing notice of the proposed collection of
information set forth in this document.
With respect to the following collection of information, FDA
invites comments on these topics: (1) Whether the proposed collection
of information is necessary for the proper performance of FDA's
functions, including whether the information will have practical
utility; (2) the accuracy of FDA's estimate of the burden of the
proposed collection of information, including the validity of the
methodology and assumptions used; (3) ways to enhance the quality,
utility, and clarity of the information to be collected; and (4) ways
to minimize the burden of the collection of information on respondents,
including through the use of automated collection techniques, when
appropriate, and other forms of information technology.
Character Space-Limited Online Prescription Drug Communications, OMB
Control Number 0910--NEW
Section 1701(a)(4) of the Public Health Service Act (42 U.S.C.
300u(a)(4)) authorizes the FDA to conduct research relating to health
information. Section 1003(d)(2)(C) of the Federal Food, Drug, and
Cosmetic Act (the FD&C Act) (21 U.S.C. 393(d)(2)(C)) authorizes FDA to
conduct research relating to drugs and other FDA regulated products in
carrying out the provisions of the FD&C Act.
Prescription drug regulations require a fair balance of the content
and prominence of risk and benefit information in prescription drug
product claim promotion. The rise of Internet communications that have
character space limitations, such as sponsored link promotion and
microblog messaging, has led to questions about how to use these
communications for prescription drug promotion while complying with the
fair balance requirements. In 2014, FDA released a draft guidance
entitled, ``Guidance for Industry Internet/Social Media Platforms with
Character Space Limitations--Presenting Risk and Benefit Information
for Prescription Drugs and Medical Devices,'' (Ref. 1) which states:
Regardless of character space constraints that may be present on
certain Internet/social media platforms, if a firm chooses to make a
product benefit claim, the firm should also incorporate risk
information within the same character-space-limited communication.
The firm should also provide a mechanism to allow direct access to a
more complete discussion of the risks associated with its product.
The concept of linking to risk information by providing substantive
product risk information on a landing page (``link to the risk
information''), rather than presenting risk information together with
product benefit information within the character-space-limited
communication, has been the subject of legislation and has been
discussed as an option by some in industry and media (for example,
Refs. 2-5).
The studies are designed to address the question of whether
substantive risk information in the character-space-limited
communications is effective in communicating risks when benefit claims
are made, or whether a link to the risk information is sufficient.
Within each study, we will manipulate whether or not substantive risk
information appears in the character-space-limited communication.
Another factor to consider is that when consumers turn to the
Internet for information, they are driven by different goals. These
goals can affect what information they pay attention to and what kind
of information they find (Refs. 6-8). Therefore, we will also
manipulate whether participants are instructed to browse the
information or to search for specific information.
Two pretests will be conducted to test the goal instructions,
stimuli, questionnaire, and procedure. In Studies 1-4, participants
will be randomly assigned to one experimental condition and will view
the corresponding study materials (Tables 1-4). Across all studies, we
will examine two different character-space-limited formats and two
medical conditions. For Pretest 1 and Study 1, the study materials will
be a character-space-limited communication about a fictional weight
loss drug, embedded in a Google search page about weight loss. The
Study 2 materials will be a character-space-limited communication about
a fictional drug to treat migraine, embedded in a Google search page
about migraine. The Study 3 materials will be a character-space-limited
communication about a fictional weight loss drug, embedded in a Twitter
search page about weight loss. The Pretest 2 and Study 4 materials will
be a character-space-limited communication about a fictional drug to
treat migraine, embedded in a Twitter search page about migraine.
All study materials will allow for scrolling and clicking on any
links. The study materials will be accessible by participants only.
After viewing the study materials, participants will complete a
questionnaire that assesses participants' retention of the risk
information and their perceptions of the drug's risks and benefits. We
will also measure covariates such as demographics and literacy. The
questionnaires are available upon request.
We hypothesize that participants who see substantive risk
information in the character-space-limited communication, compared with
link-only participants, will have greater retention of the risk
included in the communication and higher perceived risk. We will
explore whether including substantive risk information in the
character-space-limited communication affects the likelihood that
participants notice the communication or click the link to the risk
information. We hypothesize that participants with a search goal,
compared with a browse goal, will have greater retention of the benefit
and risk information and higher perceived risk because they will be
more likely to notice the character-space-limited communication and to
click the link to the risk information. We will test these hypotheses
in Studies 1-4 to determine whether these effects hold across different
medical conditions and different character-space-limited platforms. To
test these hypotheses, we will conduct inferential statistical tests
such as logistic regression and analysis of variance.
All participants will be 18 years of age or older. We will exclude
individuals who work in healthcare or marketing. Half of the studies
will have a sample of participants who self-report needing to lose 30
pounds or more; the other half will have a sample of participants who
self-report suffering from migraines. We selected these samples to
increase the likelihood that participants will be interested in the
fictitious study drugs and therefore motivated to pay attention during
the study. The studies will be conducted with an Internet panel. With
the sample sizes described below, we will have sufficient power to
detect small-sized effects in Studies 1-4 (Table 5).
[[Page 78165]]
Table 1--Study 1: Google Sponsored Link, Weight Loss
------------------------------------------------------------------------
Goal
-------------------------------
Browse Search
------------------------------------------------------------------------
Risk Location:
In character-space-limited .............. ..............
communication......................
On landing page only................ .............. ..............
------------------------------------------------------------------------
Table 2--Study 2: Google Sponsored Link, Migraine
------------------------------------------------------------------------
Goal
-------------------------------
Browse Search
------------------------------------------------------------------------
Risk Location:
In character-space-limited .............. ..............
communication......................
On landing page only................ .............. ..............
------------------------------------------------------------------------
Table 3--Study 3: Twitter, Weight Loss
------------------------------------------------------------------------
Goal
-------------------------------
Browse Search
------------------------------------------------------------------------
Risk Location:
In character-space-limited .............. ..............
communication......................
On landing page only................ .............. ..............
------------------------------------------------------------------------
Table 4--Study 4: Twitter, Migraine
------------------------------------------------------------------------
Goal
-------------------------------
Browse Search
------------------------------------------------------------------------
Risk Location:
In character-space-limited .............. ..............
communication......................
On landing page only................ .............. ..............
------------------------------------------------------------------------
FDA estimates the burden of this collection of information as
follows:
Table 5--Estimated Annual Reporting Burden \1\
----------------------------------------------------------------------------------------------------------------
Number of
Activity Number of responses per Total annual Average burden Total hours
respondents respondent responses per response
----------------------------------------------------------------------------------------------------------------
Pretest 1 screener............ 464 1 1 .08 (5 min.).... 39
Pretest 2 screener............ 464 1 1 .08 (5 min.).... 39
Study 1 screener.............. 786 1 1 .08 (5 min.).... 66
Study 2 screener.............. 786 1 1 .08 (5 min.).... 66
Study 3 screener.............. 786 1 1 .08 (5 min.).... 66
Study 4 screener.............. 786 1 1 .08 (5 min.).... 66
Pretest 1..................... 277 1 1 .33 (20 min.)... 93
Pretest 2..................... 277 1 1 .33 (20 min.)... 93
Study 1....................... 469 1 1 .33 (20 min.)... 157
Study 2....................... 469 1 1 .33 (20 min.)... 157
Study 3....................... 469 1 1 .33 (20 min.)... 157
Study 4....................... 469 1 1 .33 (20 min.)... 157
------------------------------------------------ ---------------
Total..................... 6,502 .............. .............. ................ 1,156
----------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of
information.
II. References
The following references are on display in the Division of Dockets
Management (see ADDRESSES) and are available for viewing by interested
persons between 9 a.m. and 4 p.m., Monday through Friday; they are also
available electronically at http://www.regulations.gov. FDA has
verified the Web site addresses, as of the date this document publishes
in the Federal Register, but Web sites are subject to change over time.
[[Page 78166]]
1. Guidance for Industry: Internet/Social Media Platforms with
Character Space Limitations--Presenting Risk and Benefit Information
for Prescription Drugs and Medical Devices, available at: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm401087.pdf.
2. https://www.congress.gov/bill/114th-congress/house-bill/2479/text.
3. http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm184250.htm.
4. http://www.politico.com/story/2015/06/at-the-fda-drugs-and-tweets-dont-mix-118693.
5. http://www.dtcperspectives.com/is-one-click-in-the-cards/.
6. Detlor, B., S. Sproule, and C. Gupta, ``Pre-Purchase Online
Information Seeking: Search Versus Browse.'' Journal of Electronic
Commerce Research, vol. 4, pp. 72-84, 2003.
7. Pieters, R. and M. Wedel, ``Goal Control of Attention to
Advertising: The Yarbus Implication.'' Journal of Consumer Research,
vol. 34, pp. 224-233, 2007.
8. Schlosser, A. E., ``Experiencing Products in the Virtual World:
The Role of Goal and Imagery in Influencing Attitudes Versus
Purchase Intentions.'' Journal of Consumer Research, vol. 30, pp.
184-198, 2003, http://dx.doi.org/10.1086/376807.
Dated: October 31, 2016.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2016-26793 Filed 11-4-16; 8:45 am]
BILLING CODE 4164-01-P